Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo
- 395 Downloads
The type II transmembrane serine proteases (TTSP) are cell surface proteolytic enzymes that mediate a diverse range of cellular functions, including tumour invasion and metastasis. Matriptase-2 is a member of the TTSP family and has been shown to have a key role in cancer progression. The role of matriptase-2 in angiogenesis and angiogenesis-related cancer progression is currently poorly understood. This study aims to elucidate the role of matriptase-2 in tumour angiogenesis. Matriptase-2 was over-expressed in human vascular endothelial cells, HECV, using a mammalian expression plasmid. The altered cells were used in a number of in vitro and in vivo assays designed to investigate the involvement of matriptase-2 in angiogenesis. Over-expression had no significant effect on the growth and adhesion of HECV cells. However, there was a significant reduction in the motility of the cells and their ability to form tubules in an artificial basement membrane (p < 0.01 for both). HECVmat2 exp cells inoculated into CD-1 athymic mice along with either PC-3 prostate cancer cells or MDA-MB-231 breast cancer cells showed a dramatic decrease in tumour development and growth in the prostate tumours (p < 0.01) and a lesser, non-significant, decrease in the breast tumours (p = 0.08). Over-expression of matriptase-2 also decreased urokinase type plasminogen activator total protein levels in HECV and prostate cells. The study concludes that matriptase-2 has the ability to suppress the angiogenic nature of HECV cells in vitro and in vivo. It also suggests that matriptase-2 could have a potential role in prostate and breast tumour suppression through its anti-angiogenic properties.
KeywordsMatriptase-2 TTSP Angiogenesis Prostate cancer uPA
The authors wish to thank Cancer Research Wales for supporting this study.
- 6.Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C (2002) Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 277(40):37637–37646. doi: 10.1074/jbc.M203007200 PubMedCrossRefGoogle Scholar
- 7.Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H, Quigley JP (2003) Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 373(Pt 3):689–702. doi: 10.1042/BJ20030390 PubMedCrossRefGoogle Scholar
- 10.Tsai WC, Chu CH, Yu CP, Sheu LF, Chen A, Chiang H, Jin JS (2008) Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 24(2):89–99PubMedGoogle Scholar
- 12.Parr C, Sanders AJ, Davies G, Martin T, Lane J, Mason MD, Mansel RE, Jiang WG (2007) Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res 13(12):3568–3576. doi: 10.1158/1078-0432.CCR-06-2357 PubMedCrossRefGoogle Scholar
- 13.Sanders AJ, Parr C, Martin TA, Lane J, Mason MD, Jiang WG (2008) Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol 216(3):780–789. doi: 10.1002/jcp.21460 PubMedCrossRefGoogle Scholar
- 14.Odet F, Verot A, Le Magueresse-Battistoni B (2006) The mouse testis is the source of various serine proteases and serine proteinase inhibitors (SERPINs): serine proteases and SERPINs identified in Leydig cells are under gonadotropin regulation. Endocrinology 147(9):4374–4383. doi: 10.1210/en.2006-0484 PubMedCrossRefGoogle Scholar
- 15.Overall CM, Tam EM, Kappelhoff R, Connor A, Ewart T, Morrison CJ, Puente X, Lopez-Otin C, Seth A (2004) Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 385(6):493–504. doi: 10.1515/BC.2004.058 PubMedCrossRefGoogle Scholar
- 23.Martin TA, Parr C, Davies G, Watkins G, Lane J, Matsumoto K, Nakamura T, Mansel RE, Jiang WG (2003) Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24(8):1317–1323. doi: 10.1093/carcin/bgg072bgg072 PubMedCrossRefGoogle Scholar
- 30.Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275(34):26333–26342. doi: 10.1074/jbc.M002941200 PubMedCrossRefGoogle Scholar
- 32.Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL (2008) Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 25(4):377–388. doi: 10.1007/s10585-007-9116-4 PubMedCrossRefGoogle Scholar